"Inovio (INO) Surges 17.4%: What's Next for the Stock?"

Inovio Pharmaceuticals' shares surged 17.4% following the announcement of plans to submit a biological license application for a new drug under the FDA's accelerated approval program. The company is expected to report a quarterly loss of $1.37 per share with revenues of $0.26 million, representing a year-over-year change of +45.6% and 100% respectively. While the stock currently carries a Zacks Rank #2 (Buy), investors are advised to monitor the company's earnings estimate revisions to gauge future stock price movements. Additionally, Janux Therapeutics, Inc., another company in the same industry, closed the last trading session 2.5% higher at $9.43.